FY2022 · ended Dec 31, 2022 · Revenue $125,000, +0.0% YoY · Filed Mar 28, 2024
Candel Therapeutics, Inc. (CADL) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). Free cash flow was -$38.9 million. As of Jun 30, 2026 it held $201.6 million in cash and investments and $1.7 million in total debt.
Revenue
$125,000
+0.0% vs prior year
Net income
$-38.18M
+30.8% vs prior year
Operating cash flow (TTM)
$-56.02M
-87.4% vs year-ago TTM
Free cash flow (TTM)
$-57.32M
-91.5% vs year-ago TTM
EPS
$-0.72
+58.6% vs prior year
Dividend per share
None
Shares outstanding
73.25M
+55.1% vs prior year
Net cash
$199.88M
as of Jun 30, 2026
Operating margin
-27777.6%
FY 2022
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CADL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Needham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1841387
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | $125,000 | $125,000 |
| Operating income | -$48.3M | -$33.4M | -$38.4M | -$34.7M | -$25.7M |
| Net income | -$38.2M | -$55.2M | -$37.9M | -$18.8M | -$36.1M |
| Diluted EPS | -$0.72 | -$1.74 | -$1.31 | -$0.65 | — |
| Operating cash flow | -$38.3M | -$27.0M | -$34.2M | -$31.4M | -$22.2M |
| Free cash flow | -$38.9M | -$27.0M | -$34.7M | -$32.7M | -$24.1M |
| Total assets | $125.2M | $106.9M | $41.2M | $77.7M | $89.2M |
| Total liabilities | $73.3M | $40.5M | $28.5M | $30.0M | $25.1M |
| Stockholders' equity | $51.9M | $66.3M | $12.7M | $47.7M | $64.1M |
| Cash and investments | $119.7M | $102.7M | $35.4M | $70.1M | $82.6M |
| Total debt | $1.9M | $12.6M | $22.0M | $1.9M | $560,000 |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 10, 2026 | Sep 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2026 | Sep 9, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 24, 2026 | Jun 23, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 16, 2026 | Jun 12, 2026 |
All 416 Candel Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.